2024
The role of surgery and deescalation for HPV‐related oropharyngeal cancer
Contrera K, Patel M, Burtness B, Mehra R, Ferris R. The role of surgery and deescalation for HPV‐related oropharyngeal cancer. Cancer 2024 PMID: 38497569, DOI: 10.1002/cncr.35287.Peer-Reviewed Original Research
2021
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group
Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, Burtness B, Ghi MG, Cohen EEW, Grau C, Wolf G, Hitt R, Corvò R, Budach V, Kumar S, Laskar SG, Mazeron JJ, Zhong LP, Dobrowsky W, Ghadjar P, Fallai C, Zakotnik B, Sharma A, Bensadoun RJ, Redda M, Racadot S, Fountzilas G, Brizel D, Rovea P, Argiris A, Nagy ZT, Lee JW, Fortpied C, Harris J, Bourhis J, Aupérin A, Blanchard P, Pignon JP, Group M, Adelstein D, Alfonsi M, Belkacemi Y, Bar-Ad V, Bernier J, Bratland Å, Calais G, Campbell B, Caudell J, Chabaud S, Chamorey E, Chaukar D, Choi K, Choussy O, Collette L, Cruz J, Dani C, Dauzier E, Forastiere A, Garaud P, Gregoire V, Hackshaw A, Haddad E, Haffty B, Hansen A, Hayoz S, Horiot J, Jeremic B, Karrison T, Langendijk J, Lapeyre M, Lartigau E, Leong T, Le Q, Lee P, Lewin F, Lin A, Lopes A, Mehta S, Moon J, Moyal E, Occéan B, Olmi P, Orecchia R, O'Sullivan B, Overgaard J, Petit C, Quon H, Sanguineti G, Satar T, Simes J, Simon C, Sire C, Staar S, Stromberger C, Strojan P, Temam S, Thomson D, Timochenko A, Torri V, Tseroni V, Vermorken J, Vokes E, Waldron J, Wernecke K, Widder J, Zackrisson B. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiotherapy And Oncology 2021, 156: 281-293. PMID: 33515668, PMCID: PMC8386522, DOI: 10.1016/j.radonc.2021.01.013.Peer-Reviewed Original ResearchConceptsLoco-regional treatmentConcomitant CTConcomitant chemotherapyOverall survivalNeck cancerNon-metastatic headPoor performance statusSquamous cell headIndividual patient dataNon-metastatic carcinomasAddition of inductionFixed-effects modelPerformance statusPatient ageDistant metastasisRandomized trialsMain endpointCell headStage IIIMeta-AnalysisPatientsChemotherapyPatient dataTrialsCancer
2020
354 A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer
Pai S, Adkins D, Wirth L, Chung C, Gibson M, Sukari A, Worden F, Colevas D, Saba N, Burtness B, Rodriguez C, Bauman J, Glisson B, Dunn L, Suri A, Haydock M, Quayle S, Cemerski S, Leader M, Brown J, Pienta K, Simcox M. 354 A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer. 2020, a216.1-a216. DOI: 10.1136/jitc-2020-sitc2020.0354.Peer-Reviewed Original ResearchPredictive classifier for intensive treatment of head and neck cancer
Zakeri K, Rotolo F, Lacas B, Vitzthum LK, Le Q, Gregoire V, Overgaard J, Hackshaw A, Zackrisson B, Parmar MKB, Burtness BA, Ghi MG, Sanguineti G, O’Sullivan B, Fortpied C, Bourhis J, Shen H, Harris J, Michiels S, Pignon J, Mell LK, Intergroup F. Predictive classifier for intensive treatment of head and neck cancer. Cancer 2020, 126: 5263-5273. PMID: 33017867, DOI: 10.1002/cncr.33212.Peer-Reviewed Original ResearchConceptsOverall survivalIntensive treatmentΩ scoreNeck cancerGood performance statusEffect of chemotherapyOral cavity sitesPerformance statusAdvanced headRandomized trialsControl armHigh riskN categoryPatientsRelative hazardYounger ageEvent riskEvent regressionCancerCancer progressionUnknown statusTreatment effectsChemotherapyScoresTreatmentApplications of radiomics in precision diagnosis, prognostication and treatment planning of head and neck squamous cell carcinomas
Haider SP, Burtness B, Yarbrough WG, Payabvash S. Applications of radiomics in precision diagnosis, prognostication and treatment planning of head and neck squamous cell carcinomas. Cancers Of The Head & Neck 2020, 5: 6. PMID: 32391171, PMCID: PMC7197186, DOI: 10.1186/s41199-020-00053-7.Peer-Reviewed Original ResearchNeck squamous cell carcinomaSquamous cell carcinomaCell carcinomaPatient selectionNeck cancerClinical trialsObjective biomarkersRoutine clinical applicationPrognostic biomarkerTreatment guidancePersonalized treatmentRadiomics analysisTreatment planningPrecision medicineClinical applicationCarcinomaPrecision diagnosisApplication of radiomicsPrognosticationBiomarkersRadiomicsHeadCancerDiagnosisTrialsAdjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer
Saeed NA, Kelly JR, Deshpande HA, Bhatia AK, Burtness BA, Judson BL, Mehra S, Edwards HA, Yarbrough WG, Peter PR, Holt EH, Decker RH, Husain ZA, Park HS. Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer. Head & Neck 2020, 42: 1031-1044. PMID: 32011055, DOI: 10.1002/hed.26086.Peer-Reviewed Original ResearchConceptsAnaplastic thyroid cancerLonger OSAdjuvant EBRTThyroid cancerAdjuvant external beam radiotherapyNational Cancer DatabaseExternal beam radiotherapyConcurrent chemoradiationConcurrent chemotherapyImproved survivalMedian ageCancer DatabaseRetrospective analysisBeam radiotherapyEBRTChemotherapyPatientsCancerUVAChemoradiationResectionRadiotherapyChapter 11 Trials and tribulations: Clinical trials and the future
Khanna S, Burtness B. Chapter 11 Trials and tribulations: Clinical trials and the future. 2020, 197-215. DOI: 10.1016/b978-0-12-820679-9.00011-6.Peer-Reviewed Original ResearchClinical trialsNeck cancerRecent landmark trialsRole of immunotherapyRisk stratification toolPromising clinical trialsMetastatic headPoor accrualSystemic treatmentLandmark trialsNeck specialistsStratification toolDedicated headTrialsCurrent standardCancerExciting advancesLack of fundingHeadImmunotherapyHPVHNSCCTherapyDiseasePathobiology
2019
The changing therapeutic landscape of head and neck cancer
Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nature Reviews Clinical Oncology 2019, 16: 669-683. PMID: 31189965, DOI: 10.1038/s41571-019-0227-z.Peer-Reviewed Original ResearchConceptsNeck cancerTherapeutic landscapeNeck squamous cell carcinomaFirst immunotherapeutic agentHuman papillomavirus infectionNon-surgical therapyUpper aerodigestive tractSquamous cell carcinomaDifferent treatment modalitiesPapillomavirus infectionAerodigestive tractImmunotherapeutic agentsCell carcinomaTreatment modalitiesClinical trialsOral cavitySalivary glandsWidespread testingHNSCCDevelopment of strategiesCancerCurrent eraHeadOropharynxPatientsOA01 Impact of Contralateral Lymph Node Involvement on Survival of Surgically-Managed HPV-Positive Oropharyngeal Cancer Staged with the AJCC Eighth Edition
Miccio J, Kelly J, Kann B, An Y, Park H, Verma V, Mehra S, Judson B, Burtness B, Husain Z. OA01 Impact of Contralateral Lymph Node Involvement on Survival of Surgically-Managed HPV-Positive Oropharyngeal Cancer Staged with the AJCC Eighth Edition. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e1. DOI: 10.1016/s0360-3016(19)30402-x.Peer-Reviewed Original ResearchUnique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling
Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head & Neck 2019, 41: 1928-1934. PMID: 30758123, PMCID: PMC6542589, DOI: 10.1002/hed.25634.Peer-Reviewed Original ResearchConceptsAnaplastic thyroid cancerComprehensive genomic profilingThyroid cancerGenomic alterationsGenomic profilingMedian patient ageAggressive thyroid cancerYears of agePotential therapeutic significanceUnique mutation patternsDifferent molecular pathwaysATC specimensPatient ageCommon genomic alterationsKRAS alterationsCancer-related genesBRAF V600ETherapeutic significanceCancerBRAFMolecular pathwaysPatientsMutation patternsNumber alterationsNRAS
2018
1052PD Predictor of effectiveness of treatment intensification on overall survival in head and neck cancer (HNC)
Zakeri K, Rotolo F, Lacas B, Vitzthum L, Le Q, Gregoire V, Overgaard J, Tobias J, Zackrisson B, Parmar M, Burtness B, Ghi M, Sanguineti G, O'Sullivan B, Fortpied C, Bourhis J, Shen H, Harris J, Pignon J, Mell L. 1052PD Predictor of effectiveness of treatment intensification on overall survival in head and neck cancer (HNC). Annals Of Oncology 2018, 29: viii375-viii376. DOI: 10.1093/annonc/mdy287.008.Peer-Reviewed Original ResearchOverview: The Pathobiology of Head and Neck Cancer
Burtness B, Golemis E. Overview: The Pathobiology of Head and Neck Cancer. Current Cancer Research 2018, 1-5. DOI: 10.1007/978-3-319-78762-6_1.Peer-Reviewed Original ResearchNeck cancerHPV-negative diseaseImmune checkpoint blockadeSquamous cell cancerHigh recurrence ratePathobiology of headEarly-stage cancerTumor suppressor gene mutationsSuppressor gene mutationsMultimodality therapyCheckpoint blockadeCytotoxic chemotherapyMetastatic diseaseAdvanced cancerCell cancerRecurrence rateHuman papillomavirusDevastating cancerStage cancerSubglottic larynxCancerPersonalized therapyGene mutationsPatientsTherapyP53 in Head and Neck Squamous Cell Carcinoma
Parameswaran J, Burtness B. P53 in Head and Neck Squamous Cell Carcinoma. Current Cancer Research 2018, 249-274. DOI: 10.1007/978-3-319-78762-6_9.Peer-Reviewed Original ResearchNeck squamous cell carcinomaSquamous cell carcinomaCell carcinomaMore effective treatment strategiesTreatment of headEffective treatment strategiesAdvanced diseasePoor prognosisNeck cancerTreatment strategiesPatientsP53 pathwayCarcinomaPrognosisFunction mutationsP53TP53Intracellular roleHeadPathogenesisIllnessCancerMutationsDiseaseAdjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database
Cheraghlou S, Kuo P, Mehra S, Agogo GO, Bhatia A, Husain ZA, Yarbrough WG, Burtness BA, Judson BL. Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database. Head & Neck 2018, 40: 1343-1355. PMID: 29756412, DOI: 10.1002/hed.24984.Peer-Reviewed Original ResearchConceptsNational Cancer Data BaseLate-stage diseaseAdjuvant treatmentSalivary gland cancerAdverse featuresAdjuvant radiotherapyImproved survivalGland cancerMajor salivary gland cancerAddition of chemotherapyNational Cancer DatabaseAdjuvant therapySurvival benefitRetrospective studyCancer DatabaseImproved outcomesCancer casesPatientsChemotherapyDiseaseTreatmentRadiotherapySurvivalCancerTherapyNCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.
Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 479-490. PMID: 29752322, DOI: 10.6004/jnccn.2018.0026.Peer-Reviewed Original Research
2017
The tumor genome in human immunodeficiency virus–related head and neck cancer: Exploitable targets?
Burtness B. The tumor genome in human immunodeficiency virus–related head and neck cancer: Exploitable targets? Cancer 2017, 124: 14-17. PMID: 29053184, DOI: 10.1002/cncr.31059.Peer-Reviewed Original ResearchNovel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck
Bhatia A, Burtness B. Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck. Cancers 2017, 9: 113. PMID: 28858212, PMCID: PMC5615328, DOI: 10.3390/cancers9090113.Peer-Reviewed Original ResearchNeck cancerSecond primary tumorsExtensive clinical researchCancer-related mortalityNovel molecular targetsWhole-exome sequencingBiologic agentsOral leukoplakiaInvasive cancerPrimary tumorClinical trialsPrecursor lesionsNovel molecular pathwaysPrimary headMucosal fieldTumor specimensNeck regionCare optionsClinical researchCancerDriver mutationsExome sequencingMolecular targetsGenetic mutationsMolecular pathwaysNCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.
Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. Journal Of The National Comprehensive Cancer Network 2017, 15: 761-770. PMID: 28596256, DOI: 10.6004/jnccn.2017.0101.Peer-Reviewed Original ResearchConceptsNeck cancerHuman papillomavirus-associated oropharyngeal cancerNCCN Clinical Practice GuidelinesNCCN Guidelines InsightsClinical practice guidelinesTreatment of patientsImmunotherapy agentsOccult primaryOropharyngeal cancerMost recent recommendationsTreatment recommendationsMaxillary sinusPractice guidelinesOral cavityCancerRecent recommendationsSalivary glandsHeadPatientsSinusRecommendationsRecurrentNeckOncologyPharynx(S027) Hypofractionated Radiotherapy Is associated With Improved Overall Survival Among Patients With Early-Stage Glottic Cancer
Bledsoe T, Park H, Stahl J, Yarbrough W, Burtness B, Decker R, Husain Z. (S027) Hypofractionated Radiotherapy Is associated With Improved Overall Survival Among Patients With Early-Stage Glottic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2017, 98: e8-e9. DOI: 10.1016/j.ijrobp.2017.02.063.Peer-Reviewed Original Research
2016
Treatment de-intensification strategies for head and neck cancer
Kelly JR, Husain ZA, Burtness B. Treatment de-intensification strategies for head and neck cancer. European Journal Of Cancer 2016, 68: 125-133. PMID: 27755996, PMCID: PMC5734050, DOI: 10.1016/j.ejca.2016.09.006.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Squamous CellChemoradiotherapyCombined Modality TherapyHead and Neck NeoplasmsHumansMinimally Invasive Surgical ProceduresOropharyngeal NeoplasmsOtorhinolaryngologic Surgical ProceduresPapillomavirus InfectionsRadiotherapy DosageRadiotherapy, AdjuvantSquamous Cell Carcinoma of Head and NeckConceptsHigh-risk human papillomavirus infectionHuman papillomavirus infectionLong-term morbiditySquamous cell cancerSquamous cell carcinomaDe-intensification strategiesIntensive treatment regimensAltered fractionation schemesDefinitive chemoradiationAdjuvant radiationPapillomavirus infectionCell cancerImpairs qualityTreatment regimensCell carcinomaNeck cancerRecent trialsSimilar efficacySuch cancersInvasive surgeryTreatment intensityCancerRadiation dosePreliminary dataSurgery